{"id":"onabotulinumtoxina-100-unt","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Headache"},{"rate":"5-10%","effect":"Neck pain"},{"rate":"5-10%","effect":"Injection site pain"},{"rate":"5-20%","effect":"Muscle weakness"},{"rate":"1-5%","effect":"Dysphagia"},{"rate":"1-5%","effect":"Ptosis"},{"rate":"1-3%","effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OnabotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary paralysis of injected muscles. The effect is localized to the injection site and gradually reverses over 3-4 months as new neuromuscular junctions form.","oneSentence":"OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:21.794Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Strabismus"},{"name":"Chronic migraine"},{"name":"Overactive bladder"},{"name":"Spasticity"},{"name":"Glabellar lines (aesthetic use)"}]},"trialDetails":[{"nctId":"NCT05308979","phase":"PHASE4","title":"Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2022-05-01","conditions":"Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome","enrollment":116},{"nctId":"NCT06216886","phase":"PHASE4","title":"OnabotulinumtoxinA for Trigeminal Neuralgia","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-06-01","conditions":"Trigeminal Neuralgia","enrollment":20},{"nctId":"NCT05806164","phase":"PHASE4","title":"Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2023-06-06","conditions":"Urgency Urinary Incontinence","enrollment":432},{"nctId":"NCT03726788","phase":"PHASE2","title":"Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis","status":"WITHDRAWN","sponsor":"Lille Catholic University","startDate":"2019-09","conditions":"Joint Diseases, Knee, Therapeutics","enrollment":""},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":"Urinary Bladder, Neurogenic, Multiple Sclerosis","enrollment":1},{"nctId":"NCT06250543","phase":"PHASE4","title":"Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Niko Kavcic","startDate":"2018-08-14","conditions":"Overactive Bladder","enrollment":64},{"nctId":"NCT06034288","phase":"PHASE2","title":"Xeomin vs Botox for Treatment of Overactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Walter Reed National Military Medical Center","startDate":"2023-05-04","conditions":"Overactive Bladder Syndrome","enrollment":64},{"nctId":"NCT05340439","phase":"PHASE2","title":"INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2022-06","conditions":"Spastic Cerebral Palsy","enrollment":30},{"nctId":"NCT04807920","phase":"PHASE4","title":"BOTOX® at the Time of Prolapse Surgery for OAB","status":"UNKNOWN","sponsor":"Walter Reed National Military Medical Center","startDate":"2021-09-23","conditions":"Urinary Bladder, Overactive, Pelvic Organ Prolapse","enrollment":138},{"nctId":"NCT04794504","phase":"PHASE2","title":"Investigating Temporalis and Masseter Botox Injection Before Orthognathic Surgery to Improve Postoperative Pain","status":"NOT_YET_RECRUITING","sponsor":"Kingsway Oral & Maxillofacial Surgery","startDate":"2021-04-19","conditions":"Pain, Postoperative","enrollment":64},{"nctId":"NCT03758235","phase":"PHASE3","title":"Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2018-09-01","conditions":"Overactive Bladder Syndrome","enrollment":140},{"nctId":"NCT04305743","phase":"PHASE4","title":"Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","status":"RECRUITING","sponsor":"University of South Florida","startDate":"2019-10-09","conditions":"Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX"],"phase":"marketed","status":"active","brandName":"OnabotulinumtoxinA 100 UNT","genericName":"OnabotulinumtoxinA 100 UNT","companyName":"University of South Florida","companyId":"university-of-south-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}